SCHEMBL4678098

SCHEMBL4678098

CCc1cc(OCC(=O)OC)c(C)cc1S

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HMGCR P04035 2/20 0.48
LMNA P02545 1/20 0.46
PPARG P37231 1/20 0.42
PPARD Q03181 1/20 0.42
PPARA Q07869 1/20 0.42
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 4/20 0.42
HPGD P15428 3/20 0.42
MAPK1 P28482 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
TSHR P16473 2/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
HTT P42858 1/20 0.39
CYP1A2 P05177 1/20 0.39
HSD17B10 Q99714 2/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673132 0.88 HMGCR (0.46) HMGCRLMNAPPARGPPARDPPARA
SCHEMBL4183137 0.86 LMNA (0.50) HMGCRLMNAPPARGPPARDPPARA
SCHEMBL5510093 0.83 LMNA (0.47) HMGCRLMNAPPARGPPARDPPARA
SCHEMBL4678143 0.82 LMNA (0.62) LMNAALDH1A1KDM4EHPGDMAPK1
SCHEMBL4677645 0.82 LMNA (0.46) HMGCRLMNAPPARGPPARDPPARA
SCHEMBL4677171 0.79 LMNA (0.44) HMGCRLMNAALDH1A1KDM4EHPGD
SCHEMBL8014345 0.79 LMNA (0.44) HMGCRLMNAPPARGPPARDPPARA
SCHEMBL4673174 0.78 LMNA (0.43) HMGCRLMNAALDH1A1KDM4EHPGD
SCHEMBL4680002 0.77 HMGCR (0.44) HMGCRLMNAPPARGPPARDPPARA
SCHEMBL10174850 0.76 HMGCR (0.48) HMGCRLMNAPPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1482935-B1 THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY WARNER LAMBERT CO (US) 2008-08-20 EP disclosed
EP-1482935-B1 THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY WARNER LAMBERT CO (US) 2008-08-20 EP disclosed
EP-1482935-A1 THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY Warner-Lambert Company LLC (US) 2004-12-08 EP disclosed
US-20030207924-A1 Compounds that modulate PPAR activity and methods of preparation CHENG XUE-MIN (US) 2003-11-06 US disclosed
WO-2003074050-A1 THIAZOLE AND OXAZOLE DERIVATIVES WHICH MODULATE PPAR ACTIVITY WARNER-LAMBERT COMPANY LLC (US) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207924-A1 Compounds that modulate PPAR activity and methods of preparation PPARA, PPARD, PPARG HMGCR 75/4885LMNA 1479/4885PPARG 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.